logo
explain how to read the page

The above diagram shows the color scheme of the layout in the main result page. The parent entities and officers are those entities, including individual and legal persons, have significant controls over the company in focus. The offspring entities and appointments are those entities that the company in focus can influence on.

Clicking the links on parent entities or officers, and offspring entities or managed companies will put them in focus and show upstream or downstream connections. In general, ascendant entities can be found by moving toward upstream, and descendant entities are by toward downstream. In this way, progenitor entities such as grandparent companies (parents of parent), sibling companies (children of parent), partner companies (parents of child), and progeny entities such as grandchild companies (children of child) can be found easily.

Parent entities and officers 3
  • 1
    Vincent John Green
    Individual (1 offspring)
    Insolvency
    2017-02-21 ~ now
    IP - (Case 1) practitioner → CIF 0
  • 2
    Gwatkin, Nicholas David
    Consultant born in July 1969
    Individual (3 offsprings)
    Officer
    2014-08-14 ~ now
    OF - Director → CIF 0
    Mr Nicholas David Gwatkin
    Born in July 1969
    Individual (3 offsprings)
    Person with significant control
    2016-04-06 ~ now
    PE - Right to appoint or remove directorsCIF 0
    PE - Ownership of shares – 75% or moreCIF 0
    PE - Has significant influence or controlCIF 0
    PE - Ownership of voting rights - 75% or moreCIF 0
  • 3
    Mark Newman
    Individual (900 offsprings)
    Insolvency
    2017-02-21 ~ now
    IP - (Case 1) practitioner → CIF 0
parent relation
Company in focus

GENI BIOPHARMA LIMITED

Period: 2014-08-14 ~ 2018-01-20
Company number: 09176358
Registered name
GENI BIOPHARMA LIMITED - Dissolved
Standard Industrial Classification
96090 - Other Service Activities N.e.c.
Brief company account
Please be reminded the displayed account data is older than 4 years hence might not reflect current company status.
Par Value of Share
Class 1 ordinary share
1 GBP2014-08-14 ~ 2016-01-31
Tangible fixed assets
25,000 GBP2016-01-31
Debtors
89,236 GBP2016-01-31
Cash at bank and in hand
283,197 GBP2016-01-31
Current Assets
372,433 GBP2016-01-31
Current liabilities
-138,338 GBP2016-01-31
Net Current Assets/Liabilities
234,095 GBP2016-01-31
Total Assets Less Current Liabilities
259,095 GBP2016-01-31
Called-up share capital
100 GBP2016-01-31
Retained earnings
258,995 GBP2016-01-31
Shareholder's fund
259,095 GBP2016-01-31
Cost/valuation of tangible fixed assets
37,742 GBP2016-01-31
Depreciation expense of tangible fixed assets in the period
12,742 GBP2014-08-14 ~ 2016-01-31
Depreciation of tangible fixed assets
12,742 GBP2016-01-31
Number of shares allotted
Class 1 ordinary share
100 shares2016-01-31
Paid-up share capital
Class 1 ordinary share
100 GBP2016-01-31

  • GENI BIOPHARMA LIMITED
    Info
    Registered number 09176358
    4 Mount Ephraim Road, Tunbridge Wells, Kent TN1 1EE
    PRIVATE LIMITED COMPANY incorporated on 2014-08-14 and dissolved on 2018-01-20 (3 years 5 months). The status of the company number is Dissolved.
    CIF 0
child relation
Offspring entities and appointments 0
  • Not found in our database.

The content of this website is protected by AgonGuard.

© 2022- Polylogarithmic Technology Ltd (Registered in England and Wales No. 14256313). All rights reserved.

Contains public sector information retrieved at 22 April 2026 and licensed under the Open Government Licence v3.0.